• darkblurbg

    Developing therapies

    for type 1 diabetes

  • darkblurbg

    Intralymphatic immunotherapy

    with Diamyd®

Biostatistician or Data Scientist with Life Science experience

We welcome candidates with relevant life science experience to join our team.


 Dates for financial information and other events
February 10 − February 11, 2021
Swiss Nordic Bio 2021
March 31, 2021
Quarterly Report II
Quarterly Report 2 2020/2021
June 23, 2021
Quarterly Report III
Quarterly Report 3 2020/2021
October 6, 2021
Year-End Report
Year-End Report 2020/2021

Company Presentation

The collected genetic and immunological insights support the possibility that we may be able to truly individualize the treatment.

Ulf Hannelius
President and CEO, Diamyd Medical AB
CEO Comments, Quarterly Report 1 20/21


Diamyd Medical develops therapies for type 1 diabetes
The share is listed on Nasdaq First North Growth Market (ticker: DMYD B)

Read More

Order GAD for preclinical research